Foley Hoag Represents Pervasis Therapeutics in Deal With Shire
April 24, 2012
Foley Hoag LLP represented Pervasis Therapeutics in connection with a sale of substantially all of Pervasis’ assets to a subsidiary of Shire plc.
The deal provided Pervasis with an upfront payment, plus potential post-closing payments that are dependent on Shire’s achievement of certain clinical-development, regulatory and net-sales milestones. The U.K.-based Shire acquired Pervasis’ lead product Vascugel, which is currently in Phase 2 development for acute vascular repair, focused on improving hemodialysis access for patients with end-stage renal disease.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.